Regenerative Medicine News
Mesoblast: Market Update
Mesoblast: Market Update
November 19, 2012 - (Mesoblast) - "Regenerative medicine company, Mesoblast Limited, has become aware of certain statements in the market in regard to its relationship with Teva Pharmaceutical Industries Ltd. As stated last week in response to the ASX share price query, Mesoblast and Teva are committed to jointly developing innovative products for major cardiovascular and neurologic markets. The lead product in this alliance is for congestive heart failure." Read Full Article
Posted on
27-Nov-12
by Gallerno, Jacob
Tags:
Science and Industry News
Trackback Url
|
Link to this post
| Bookmark this post with:
